Digest Network Come funziona
Network
/
Società
Sa
Non verificato

Savara Inc.

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaMedicina - VarieSalute

84 comunicati stampa

Guarda tutti i comunicati
12/06/2026
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Savara Announces New Employment Inducement Grant
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
08/06/2026
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Savara Announces Chief Financial and Administrative Officer Transition
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Web e Social Network
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
20/05/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Industria
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
19/05/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
18/05/2026
Eventi
Fiere
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Mercato azionario
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Savara Reports First Quarter Financial Results and Provides Business Update
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
11/05/2026
Web e Social Network
Eventi
Fiere
Biotecnologia
Farmaceutica
Salute
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
17/04/2026
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Savara Announces New Employment Inducement Grant
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
15/04/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0